Aptevo Therapeutics Inc. reported its financial results for the year ended December 31, 2024, and provided a comprehensive business update. The company highlighted significant clinical progress, including 100% of patients achieving remission within 30 days in Cohort 1 of the Mipletamig RAINIER Dose Optimization Trial for Frontline AML Patients.
The update also featured promising data from the ALG.APV-527 Phase 1 Trial for the Treatment of Multiple Solid Tumors, which demonstrated a 59% Stable Disease Rate. These results make a strong case for the continued development of this first-in-class anti-cancer agent, showcasing the potential of Aptevo's proprietary ADAPTIR® and ADAPTIR-FLEX® platform technologies.
Trial enrollment for mipletamig continues, indicating ongoing momentum in its clinical development. The company emphasized that 2024 was a successful year, demonstrating the power of its scientific approach and its commitment to advancing oncology care through novel immune-oncology therapeutics.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.